LAVA Therapeutics reviews strategic options amid cost cuts. HC Wainwright downgrades stock, citing uncertainties over LAVA-1266 and possible business shifts.
Latest Ratings for LVTX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2021 | SVB Leerink | Maintains | Outperform | |
| Aug 2021 | SVB Leerink | Maintains | Outperform | |
| Apr 2021 | Jefferies | Initiates Coverage On | Buy |
